C12N 2710/10062
By genetic engineering
Official title: by genetic engineering
C12N2710/10062 (By genetic engineering) appears on 3 US grants and 5 published applications in this corpus.
Search patents in C12N- Granted patents
- 3
- Published applications
- 5
- Assignees
- 4
- Inventors
- 19
- Latest grant
- 1 Mar 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2018 | 0 | 3 |
| 2019 | 1 | 0 |
| 2020 | 1 | 1 |
| 2021 | 0 | 0 |
| 2022 | 1 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Promoters1 Mar 2022US 11,261,464 B2
- Human type 55 replication defective adenovirus vector, method for preparing same and uses thereof1 Sep 2020US 10,760,096 B2Guangzhou N Biomed Co., Ltd.
- Ebola virus disease vaccine taking human replication deficient adenovirus as vector8 Jan 2019US 10,172,932 B2Institute of Biotechnology, Academy of Military Medical Science, PLA
- Recombinant Viral Genomes and Related Compositions and Methods24 Jul 2025US 2025/0235493 A1
- Adenovirus control virus2 Jul 2020US 2020/0208173 A1Seracare Life Sciences, Inc.
- Ebola Virus Disease Vaccine Taking Human Replication Deficient Adenovirus As Vector20 Sep 2018US 2018/0264100 A1Institute of Biotechnology, Academy of Military Medical Science, PLA
- Human type 55 replication defective adenovirus vector, method for preparing same and uses thereof28 Jun 2018US 2018/0179554 A1Guangzhou N Biomed Co., Ltd.
- Promoters22 Mar 2018US 2018/0080047 A1Boehringer Ingelheim Vetmedica GmbH
Most cited
By later US patents